Pazopanib effective for bevacizumab‐unresponsive epistaxis in hereditary hemorrhagic telangiectasia
- 16 February 2018
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 128 (10) , 2234-2236
Abstract
Hereditary hemorrhagic telangiectasia (HHT) most commonly manifests with nasal mucosal telangiectasias, and vascular endothelial growth factor (VEGF) plays a significant role in this angiodysplasia. We describe a patient with HHT with epistaxis recalcitrant to several endonasal procedures and six cycles of intravenous bevacizumab, for which he was dependent on iron infusions and packed red blood cells transfusions. He then started pazopanib at 100 mg with dramatic improvements in epistaxis and normalization of hemoglobin and iron levels, without replenishment needs for 12 months. This is the first report on the efficacy of pazopanib with high selectivity for abrogating VEGF receptor‐2 signaling in HHT, and needs to be explored further. Laryngoscope, 128:2234–2236, 2018Keywords
This publication has 14 references indexed in Scilit:
- Transforming growth factor β family members in regulation of vascular function: In the light of vascular conditional knockoutsExperimental Cell Research, 2013
- Safety and tolerability of pazopanib in the treatment of renal cell carcinomaExpert Opinion on Drug Safety, 2012
- Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasiaAmerican Journal of Otolaryngology, 2012
- Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapyThe Laryngoscope, 2011
- Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxisActa Ophthalmologica, 2011
- Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasiaBritish Journal of Haematology, 2010
- The Role of VEGF Pathways in Human Physiologic and Pathologic AngiogenesisJournal of Surgical Research, 2010
- International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasiaJournal of Medical Genetics, 2009
- Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?Ophthalmology, 2008
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007